Klinische Diagnostik, Klassifikation

S. Schreiber; U. R. Fölsch

doi:10.1055/s-2003-36662

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2003; 41(1): 21-23
DOI: 10.1055/s-2003-36662

Leitlinien der DGVS

Klinische Diagnostik, Klassifikation

Clinical Diagnostics, ClassificationS. Schreiber¹ , U. R. Fölsch¹

¹Medizinische Universitätsklinik, Kiel

Abstract

Full Text

References

Literatur

1 Hugot J P, Chamaillard M, Zouali H. et al . Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001; 411 599-603 (III)
2 Hampe J, Cuthbert A, Croucher P JP. et al . An insertion mutation in the NOD2 gene predisposes to Crohn’s Disease in the German and British populations. Lancet. 2001; 357 1925-1928 (III)
3 Ogura Y, Bonen D K, Inohara N. et al . A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature. 2001; 411 603-606 (III)
4 Cuthbert A P, Fisher S A, Mirza M M. et al . The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology. 2002; 122 867-874 (III)
5 Hampe J, Grebe J, Nikolaus S. et al . The NOD2 genotype and the clinical course of Crohn’s disease. Lancet. 2002; 359 1661-1665 (III)
6 Mascheretti S, Hampe J, Kühbacher T. et al . Pharmacogenetic Investigation of the TNF/TNF-Receptor System in Patients with Chronic Active Crohn’s Disease Treated with Infliximab. Pharmacogenomics J. 2002; 2 127-136 (III)
7 Mascheretti S, Hampe J, Croucher P JP. et al . Response to infliximab treatment in Crohn’s disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics. 2002; 12 509-515 (III)
8 Fischbach W, Becker W, Mossner J. et al . Faecal alpha-1-antitrypsin and excretion of 111indium granulocytes in assessment of disease activity in chronic inflammatory bowel diseases. Gut. 1987; 28 386-393 (III)
9 Tibble J A, Sigthorsson G, Bridger S. et al . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119 15-22 (III)
10 Brignola C, Campieri M, Bazzochi G. et al . A laboratory index for predicting relapse in asymptomatic patients with Crohn’s disease. Gastroenterology. 1986; 91 1490-1494 (III)
11 Wyatt J, Vogelsang H, Hubl W. et al . Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet. 1993; 341 1437-1439 (III)
12 Schreiber S, Nikolaus S, Hampe J. et al . Tumor Necrosis Factor-a and Interleukin 1ß in Relapse of Crohn’s Disease. Lancet. 1999; 353 459-461 (III)
13 Nikolaus S, Raedler A, Sfikas N. et al . Mechanisms in failure of infliximab for Crohn’s disease. Lancet. 2000; 356 1475-1479 (IIb)
14 van Oostayen J A, Wasser M N, Griffioen G. et al . Diagnosis of Crohn’s ileitis and monitoring of disease activity: Value of Doppler ultrasound of superior mesenteric artery flow. Am J Gastroenterol. 1998; 92 88-91 (III)
15 Ludwig D, Wiener S, Bruening A. et al . Mesenteric blood flow is related to disease activity and risk of relapse in Crohn’s disease: A prospective follow up study. Am J Gastroenterol. 1999; 94 2942-2950 (III)
16 Heyne R, Ricke S, Bock P. et al . Non-invasive evaluation of activity in inflammatory bowel disease by Power Doppler sonography. Z Gastroenterol. 2002; 40 171-175 (III)
17 Umschaden H W, Szolar D, Gasser J. et al . Small-bowel disease: Comparison of MR enteroclysis images with concentional enteroclysis and surgical findings. Radiology. 2000; 215 717-725 (III)
18 GETAID r epresented by Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: A prospective, multicentre study. Gut. 1989; 30 983-89 (III)
19 Bernstein C N, Blanchard J F, Kliewer E. et al . Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91 854-862 (III)
20 Rubio C A, Befrits R. Colorectal adenocarcinoma in Crohn’s disease: a retrospective histologic study. Dis Colon Rectum. 1997; 40 1072-1078 (III)
21 Best W R, Becktel J M, Singleton J W. et al . Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976; 70 439-444 (III)
22 Goebell H, Wienbeck M, Schomerus H. et al . Evaluation of the Crohn’s Disease Activity Index (CDAI) and the Dutch Index for severity and activity of Crohn’s disease. An analysis of the data from the European Cooperative Crohn’s Disease Study. Med Kli. 1990; 85 573-576 (III)
23 van Hees P A, van Elteren P H, van Lier H J. et al . An index of inflammatory activity in patients with Crohn’s disease. Gut. 1980; 21 279-286 (III)
24 Harvey R F, Bradshaw J M. A simple index of Crohn’s-disease activity. Lancet. 1980; 1 514 (III)
25 Gasche C, Scholmerich J, Brynskov J. et al . A simple classification of Crohn’s disease: Report of the Working Party for the World Congress of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000; 6 8-15 (IV)
26 Louis E, Collard A, Oger A F. et al . Behaviour of Crohn’s disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49 777-782 (III)